Sort
15,842 grants matching “pancreatic cancer”
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
$599,573Diana Zepeda-Orozco · Research Inst Nationwide Children'S Hosp · R01 · FY2025 · CA
Stromal targeting to improve the efficacy of systemically administered drugs for pancreatic ductal adenocarcinomas
$599,474Luis Solorio · Purdue University · R01 · FY2024 · CA
Serum Proteomic Biomarkers for Colon & Pancreatic Cancer
$599,404William L Bigbee · University Of Pittsburgh At Pittsburgh · U01 · FY2008 · CA
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci
$599,360Alison P Klein · Johns Hopkins University · R01 · FY2012 · CA
IGF::OT::IGF PREVENT EFFICACY: OPTIMIZATION OF GEM MODELS FOR HIGH-RISK COHORTS OF HUMAN PANCREATIC CYSTADENOMAS, IPMNS, AND PANINS PROGRESSION TO PDAC.
$599,353Chinthalapally Rao · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2015 · CA
Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity
$599,268Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2021 · CA
Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity
$599,268Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2020 · CA
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
$599,074Eduard A. Sergienko · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · CA
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
$599,069Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2021 · CA
Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model
$598,999Ryan C Fields · Washington University · R01 · FY2021 · CA
Multi-Parameter Monitoring of Breast Cancer Progression and Therapeutic Response
$598,918Anna Moore · Massachusetts General Hospital · R01 · FY2009 · CA
Defining metabolic adaptations within the PDAC "arid" tumor microenvironment
$598,666Chi V. Dang · Wistar Institute · R01 · FY2021 · CA
Immune Enhancement and Therapy of Cancer
$598,634Douglas Hanahan · University Of California, San Francisco · U01 · FY2007 · CA
Mechanistic Pharmacokinetics and Pharmacodynamics
$598,595William J Jusko · State University Of New York At Buffalo · R35 · FY2021 · GM
Biological Functions of Chromosomal Proteins
$598,591Michael Bustin · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Biophotonics to Couple Pancreatic with Upper GI Screening via Ultrathin Endoscopy
$598,589Vadim Backman · Northwestern University · R01 · FY2019 · CA
Mechanistic Pharmacokinetics and Pharmacodynamics
$598,456William J Jusko · State University Of New York At Buffalo · R35 · FY2020 · GM
PROFILING SIGNALING ACTIVITY AND GENE EXPRESSION IN SINGLE, PANCREATIC ADENOCARCINOMA CELLS USING CE-RNA-SEQ
$598,406Nancy L Allbritton · University Of Washington · R01 · FY2020 · CA
New Therapuetics for Pancreatic Cancer
$598,329Martin Ernesto Fernandez-Zapico · Mayo Clinic Rochester · R01 · FY2025 · CA
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy
$598,284Eric Collisson · University Of California, San Francisco · R01 · FY2023 · CA
Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to Bedside
$598,146Debabrata Mukhopadhyay · Mayo Clinic Jacksonville · R01 · FY2017 · CA
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications
$598,029Michael John Evans · University Of California, San Francisco · R01 · FY2024 · EB
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure
$598,023Shyam Sharan · Division Of Basic Sciences - Nci · ZIG · FY2019 · CA
Clinical Trials of Flavopiridol with Chemotherapy
$597,983Sloan-Kettering Institute For Cancer Res · R01 · FY2004 · CA
Mechanistic Pharmacokinetics and Pharmacodynamics
$597,804William J Jusko · State University Of New York At Buffalo · R35 · FY2023 · GM